GPATCH1 Inhibitors
GPATCH1 Inhibitors are a class of chemical compounds that indirectly affect the functional activity of GPATCH1, a protein presumed to be involved in mRNA splicing as part of spliceosomal complexes. These inhibitors target various signaling pathways or cellular processes that can influence the activity of GPATCH1. Rapamycin, for example, inhibits the mTORC1 complex, potentially reducing the splicing activity where GPATCH1 is thought to function. Similarly, K252a and staurosporine are kinase inhibitors that can affect GPATCH1 by reducing the activity of PKC and other kinases, which may phosphorylate substrates relevant to GPATCH1's function. Ro-31-8220 specifically inhibits PKC, potentially disrupting GPATCH1's activity by affecting protein-protein interactions vital for its function in splicing.
Wortmannin and LY294002 inhibit the PI3K/AKT pathway, which can regulate protein interactions and complex assembly; their action may disrupt processes essential for GPATCH1 function. U0126 and SP600125 inhibit the MAPK/ERK and JNK pathways, respectively. Since these pathways can regulate factors that affect spliceosomeassembly and function, the inhibitors could indirectly reduce GPATCH1 activity by altering the nuclear environment and regulatory mechanisms. Alsterpaullone and roscovitine, as cyclin-dependent kinase inhibitors, may impair cell cycle-related RNA processing activities, thereby affecting GPATCH1's role in these processes. Harmine's inhibition of DYRKs can alter the phosphorylation status of splicing factors, which might be necessary for GPATCH1's function in mRNA splicing.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that impedes the mTORC1 complex. Since GPATCH1 may be involved in the mRNA splicing process as part of spliceosomal complexes, inhibition of mTOR signaling can reduce the splicing activity, potentially downregulating GPATCH1 function in mRNA processing. | ||||||
K-252a | 99533-80-9 | sc-200517 sc-200517B sc-200517A | 100 µg 500 µg 1 mg | $129.00 $214.00 $498.00 | 19 | |
Protein kinase inhibitor that targets several kinases including PKC. GPATCH1's activity could be affected by PKC-mediated phosphorylation; thus, K252a may indirectly inhibit GPATCH1 by reducing PKC activity and its subsequent phosphorylation targets. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad-spectrum kinase inhibitor that can reduce phosphorylation of a wide array of substrates. Phosphorylation often regulates protein-protein interactions; inhibition by staurosporine might disrupt interactions necessary for GPATCH1's splicing function. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
PKC inhibitor that impedes the activity of conventional and novel PKCs. Given that GPATCH1 might depend on PKC-mediated signaling for proper function, Ro-31-8220 can inhibit this pathway, likely affecting GPATCH1 activity. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
Adenosine kinase inhibitor that also inhibits other kinases. By modulating kinase activity, 5-Iodotubercidin may disrupt phosphorylation-dependent processes that are critical for GPATCH1 function in spliceosome assembly or activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that attenuates the PI3K/AKT pathway. Since PI3K signaling can regulate various protein-protein interactions and the assembly of multi-protein complexes, Wortmannin can indirectly inhibit GPATCH1 by disrupting its associated complexes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that blocks the PI3K/Akt pathway. LY294002 might affect GPATCH1 function by altering signaling cascades that modulate the spliceosome, where GPATCH1 is assumed to function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that prevents activation of the MAPK/ERK pathway. If GPATCH1's function is regulated by MAPK/ERK signaling, U0126 could indirectly inhibit its activity through pathway modulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that impedes the JNK signaling pathway. JNK activity can influence various nuclear factors; thus, SP600125 may indirectly inhibit GPATCH1 by altering the nuclear environment it operates within. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Cyclin-dependent kinase inhibitor that could interfere with cell cycle progression. Since GPATCH1 is involved in RNA processing, which is crucial during cell cycle phases, Alsterpaullone may impair GPATCH1's function indirectly through cell cycle inhibition. | ||||||